Put companies on watchlist
Alzchem Group AG
ISIN: DE000A2YNT30
WKN: A2YNT3
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Alzchem Group AG · ISIN: DE000A2YNT30 · EQS - Company News (79 News)
Country: Germany · Primary market: Germany · EQS NID: 1287195
24 February 2022 07:00AM

Alzchem Group AG: new record levels for sales, EBITDA and annual result in the fiscal year 2021


DGAP-News: Alzchem Group AG / Key word(s): Annual Results/Annual Report
Alzchem Group AG: new record levels for sales, EBITDA and annual result in the fiscal year 2021

24.02.2022 / 07:00
The issuer is solely responsible for the content of this announcement.


Alzchem Group AG: new record levels for sales, EBITDA and annual result in the fiscal year 2021

  • Sales increase to EUR 422.3 million (+11.3%)
  • EBITDA grows to EUR 62.0 million (+15.2%)
  • Annual result climbs to EUR 27.8 million (+39.7%)
  • Dividend increase from EUR 0.77 per share to EUR 1.00 per share planned

Trostberg, 24 February 2022 - Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, can look back on an extremely successful fiscal year 2021. Despite COVID-19, supply shortages, extremely volatile raw material prices, severely impacted logistics chains and freight bottlenecks, Alzchem successfully performed as a robust company - primarily thanks to its broad product portfolio and "Verbund production", which once again proved to be a key component of raw material supply and production planning. Thus, Alzchem succeeded in exceeding the previous year's figures for sales, earnings before interest, taxes, depreciation and amortization (EBITDA), and result for the period in all four quarters of 2021. Over the year as a whole, consolidated sales rose by 11.3% to EUR 422.3 million (2020: EUR 379.3 million). The two segments Specialty Chemicals (+6.3%) and Basics & Intermediates (+20.4%) contributed equally to this new record figure. Growth in the metallurgy, pharmaceutical raw materials and human nutrition (Creapure(R)) markets in particular, flanked by high capacity utilization in the multi-purpose plants, had a positive impact on the sales increase of the Group.

On the earnings side, Alzchem also achieved new highs. The significant cost increases for energy and raw materials were at least partially offset by early stockpiling, production cost savings as a result of the "AlzFit 2025" optimization project, and contractually fixed price escalator clauses. In terms of earnings, EBITDA increased by 15.2% to EUR 62.0 million (2020: EUR 53.8 million), thus reaching a new record level. The resulting EBITDA margin was 14.7% (2020: 14.2%). Consolidated annual result increased significantly by 39.7% to EUR 27.8 million (2020: EUR 19.9 million). Due to the extremely positive business development in 2021, the Management Board and Supervisory Board will propose to the Annual General Meeting to distribute a dividend of EUR 1.00 (previous year: EUR 0.77).

Andreas Niedermaier, CEO of Alzchem Group AG: "Our company has performed very successfully in an extremely challenging environment in 2021. We were able to fully meet our forecast, which was adjusted upwards in July, and thus very significantly exceed our original targets for sales and EBITDA. In addition, we succeeded in commissioning two further major projects in 2021 within an ambitious cost and schedule framework. While the expanded NITRALZ(R) production capacities are having a positive impact on sales volumes and revenue development, the new regenerative thermal exhaust air purification plant is making an additional contribution to environmental protection. Our highly motivated and extremely flexible team of employees also made a very significant contribution to the successful fiscal year 2021, and I would like to express my sincere thanks to them for their tireless commitment and outstanding performance."

The Alzchem Group is planning further growth for the fiscal year 2022. Forecasts call for a strong to particularly strong increase in sales (up to EUR 480 million) and, due to the still uncertain framework conditions (COVID-19, raw material supply, logistics), a noticeably declining to particularly strong increasing EBITDA (up to EUR 68 million). At the top of the priority list are the significant expansion and commissioning of the Creapure(R) production capacities by the end of the third quarter of 2022 at the latest, as well as even higher utilization of the NITRALZ(R) and Creamino(R) production capacities to further drive organic growth. In addition, the aim is to further exploit the potential of the products in the respective markets, to further optimize the product mix, to remain able to deliver at all times and, in doing so, to further secure margin development also through price adjustments.

The Annual Report 2021 is available for download on the website www.alzchem.com under Investor Relations/Publications.

About Alzchem
Alzchem is a globally active specialty chemicals company that is predominantly among the market leaders in its fields of activity. Alzchem benefits in particular from the three very different global developments of climate change, population growth and longer life expectancy. In order to achieve the resulting social goals, Alzchem products can offer attractive solutions with a wide range of different applications.

The company sees interesting growth prospects for itself especially in the areas of human and animal nutrition and agriculture. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and our creatine products can contribute to healthy aging as life expectancy increases. Alzchem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective.

The broad product range of Alzchem Group AG includes dietary supplements, precursors for corona tests and pharmaceutical raw materials. These products are our company's response to global trends and developments. Alzchem is ideally positioned in this regard and sees itself as well equipped for an environmentally oriented future and global developments.

The company employs around 1,630 people at four production sites in Germany and one plant in Sweden, as well as two sales companies in the USA and China. In 2021, Alzchem generated consolidated sales of around EUR 422.3 million and EBITDA of around EUR 62.0 million.



24.02.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
Phone: +498621862888
Fax: +49862186502888
E-mail: ir@alzchem.com
Internet: www.alzchem.com
ISIN: DE000A2YNT30
WKN: A2YNT3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart
EQS News ID: 1287195

 
End of News DGAP News Service

1287195  24.02.2022 

fncls.ssp?fn=show_t_gif&application_id=1287195&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Alzchem Group AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.